Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.

Bonifati, C; De Felice, C; Lora, V; Morrone, A; Graceffa, D

Bonifati, C; De Felice, C; Lora, V; Morrone, A; Graceffa, D.

Afiliação

Bonifati C; Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
De Felice C; Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Lora V; Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Morrone A; Scientific Direction, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Graceffa D; Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

J Dermatolog Treat ; 31(7): 687-691, 2020 Nov.

Article em En | MEDLINE | ID: mdl-30985223

Assuntos

Artrite Psoriásica/tratamento farmacológico; Medicamentos Biossimilares/uso terapêutico; Etanercepte/uso terapêutico; Antirreumáticos/uso terapêutico; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Medidas de Resultados Relatados pelo Paciente; Projetos de Pesquisa; Índice de Gravidade de Doença; Resultado do Tratamento

Palavras-chave

Psoriasis; SB4; arthritis; biosimilar; etanercept

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Artrite Psoriásica / Medicamentos Biossimilares / Etanercepte Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Dermatolog Treat Assunto da revista: DERMATOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google